JACOBS SOLUTIONS INC

Raymond James Financial (RJF) has seen a 69% share price gain over the past five years, supported by record revenue, earnings, and client assets, with $1.7 billion returned to shareholders. Despite this strong performance, Simply Wall St's Excess Returns model suggests the stock may still be undervalued, with an estimated intrinsic value substantially above its current share price of $157.22. Analysts' forecasts indicate sustainable solid returns on a growing capital base, leading to a community narrative that views RJF as 15% undervalued.

Alexandria Real Estate Equities (NYSE:ARE) has an average "Reduce" rating from 16 brokerages, with an average 12-month price target of $49.36. The REIT recently reported a quarterly loss of $3.74 per share, missing estimates, although revenue exceeded expectations. Despite institutional ownership of 96.54% and a 7.2% dividend yield, the stock faces pressure as executives have reduced their holdings.

Before you break out your beans and get brewing your next morning cup of coffee, listen up. A popular French press coffee maker has just been recalled for breaking and causing serious burn injuries. Here's...

By October 29, 2026 / 5:09 PM EDT / CBS News Add CBS News on...

This article details the impressive returns an investor would have seen if they had invested $100 in Johnson Controls Intl (NYSE: JCI) five years ago. The company has outperformed the market, yielding an average annual return of 16.21%, which would have grown an initial $100 investment to $213.85 today. The piece emphasizes the power of compounded returns over time.

Raymond James Financial reported record net revenues of $4.27 billion and record net income for both the fourth quarter and fiscal year 2026, marking its sixth consecutive year of record annual results. The Private Client Group saw strong growth with client assets under administration reaching $1.87 trillion and net new assets increasing by 88% to over $98 billion. The company made significant investments in technology and AI, including its proprietary AI assistant, Raymond, to enhance advisor efficiency and client service, and management expressed optimism for fiscal 2027 with a strong investment banking pipeline.

Bausch Health Companies reported strong third-quarter results, exceeding $1 billion in quarterly adjusted EBITDA for the first time and marking 14 consecutive quarters of growth. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted cash flow, driven by strong performance in Salix, International, and Solta Medical segments. Management also discussed debt reduction efforts, capital allocation, and future strategic priorities, including pipeline development and operational excellence, while acknowledging anticipated Q4 headwinds related to Xifaxan.

State Street EVP W. Hu sold 7,099 shares of the company's stock for a total of $1,197,104.37, reducing his holdings by 14.26%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Following the sale, State Street's shares rose 1.5% to $173.39, and the company reported adjusted earnings of $3.69 per share, slightly exceeding estimates, with revenue growth of 12.9% year over year.